Adil Katabay, MD
Pain Medicine · Marion, OHNPI 1346204039
Payments from drug & device makers
Across 175 payments — averaging $26.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis BE Inc$1K
- Collegium Pharmaceutical, Inc.$651
- Protega Pharmaceutials Inc$649
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$381
- AbbVie$267
- Biodelivery Sciences International, Inc.$218
- plus $1K from 30 others
What the payments were for
- Speaking & faculty fees$60013%
- Food & beverage$3,94586%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis BE Inc | 1 | $1,215 |
| Collegium Pharmaceutical, Inc. | 46 | $651 |
| Protega Pharmaceutials Inc | 5 | $649 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $381 |
| AbbVie(2 entities) | 14 | $267 |
| Biodelivery Sciences International, Inc. | 15 | $218 |
| Amgen(2 entities) | 7 | $101 |
| Scilex Pharmaceuticals Inc. | 4 | $77 |
| Merz North America, Inc. | 3 | $75 |
| Teva Pharmaceuticals USA, Inc. | 5 | $71 |
| Boston Scientific | 4 | $67 |
| Arbor Pharmaceuticals, Inc. | 3 | $66 |
| Azurity Pharmaceuticals, Inc. | 4 | $63 |
| Novartis | 5 | $62 |
| Abbott | 3 | $54 |
| Pfizer | 4 | $52 |
| Forte Bio-pharma LLC | 3 | $51 |
| Lundbeck LLC | 3 | $50 |
| Si-bone, Inc. | 3 | $48 |
| Medline Industries LP | 1 | $48 |
| Hikma Pharmaceuticals USA | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Currax Pharmaceuticals LLC | 2 | $32 |
| Lilly USA, LLC | 2 | $27 |
| Pacira Pharmaceuticals Incorporated | 1 | $24 |
| Galderma Laboratories, L.p. | 1 | $24 |
| MDD US Operations, LLC | 2 | $23 |
| GRT US Holding, Inc. | 2 | $23 |
| Vertex | 1 | $18 |
| Sanofi | 1 | $18 |
| Averitas Pharma Inc. | 1 | $17 |
| Medtronic | 1 | $15 |
| Zyla Life Sciences, Inc. | 1 | $14 |
| Nevro Corp. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $12 |
| Supernus Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- M22$1,215
How this compares
$4,605 in reported general payments places this provider in the 65th percentile of 245 pain medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 464 | $321,537 |
| OxycontinOxycodone Hcl | 244 | $123,050 |
| RelistorMethylnaltrexone Bromide | 43 | $117,852 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 3,633 | $110,841 |
| BelbucaBuprenorphine Hcl | 41 | $31,280 |
| Aimovig AutoinjectorErenumab-Aooe | 35 | $26,151 |
| Fentanyl | 199 | $25,163 |
| MovantikNaloxegol Oxalate | 62 | $25,090 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 871 | $23,529 |
| Gabapentin | 1,947 | $22,345 |
| Celecoxib | 875 | $21,344 |
| Lidocaine | 93 | $20,428 |
| Naloxone Hcl | 328 | $18,754 |
| Tizanidine Hcl | 2,511 | $18,563 |
| Diclofenac Sodium | 178 | $14,543 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $651 | $352,817505 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $381 | $117,85243 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $35 | $4,75658 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 245 pain medicine providers in Ohio.
Other pain medicine in Marion
- Priyesh MehtaDayton$2.2M
- Joseph AtallahToledo$1.2M
- Michael DankoLoveland$1.1M
- Tristan WeaverColumbus$799K
- Nagy MekhailCleveland$687K
- Robert BolashCleveland$640K
- Alexander EscobarToledo$639K
- Henry VuceticWilloughby$510K
- Tammy DannDayton$431K
- Jijun XuCleveland$332K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.